Patent · US Active

Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof

US11292848B2 · kind B2 · utility

3Cited by

72References

20Claims

0Family size

Assignees

PROMETHEUS BIOSCIENCES, INC. · US
Cedars Sinai Medical Center · US

Inventors

Jeffry D. Watkins · Encinitas, US
Cindy T. Dickerson · Encinitas, US
Rafael Rojas · San Marcos, US
Matthew Reissman · San Diego, US
Patricia McNeeley · San Diego, US
Janine Bilsborough · Simi Valley, US
Bradley Henkle · West Hollywood, US
Stephan R. Targan · Santa Monica, US

Key dates

Filing date	Dec 2, 2020
Grant date	Apr 5, 2022
Priority date	—
Expiry date	Dec 2, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.